First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Why It Matters

The data introduces a non‑insulin adjunct that could address the longstanding weight‑gain and insulin‑dose challenges in type 1 diabetes, potentially reshaping standard care and reducing long‑term complications.

Key Takeaways

• Acmopatide lowered A1C by 0.34% at 4.1 mg dose
• 56% of participants reached A1C <7% target
• Weight loss up to 7% observed, dose‑dependent
• Insulin dose reduced up to 15% versus placebo
• First GLP‑1/GIP agonist specifically designed for type 1 diabetes

Pulse Analysis

The prevalence of type 1 diabetes in the United States—about 1.2 million adults—combined with a 64 % obesity rate creates a therapeutic gap that insulin alone cannot fill. While insulin remains essential, its anabolic effects often drive weight gain, heightening cardiovascular and renal risk. Incretin‑based therapies, long used in type 2 diabetes, mimic gut hormones GLP‑1 and GIP to improve glucose regulation, curb appetite, and promote weight loss. Acmopatide represents the first effort to harness this mechanism for type 1 patients, offering a potential paradigm shift toward a more holistic metabolic management.

The randomized, placebo‑controlled phase 2 study enrolled 111 overweight adults with baseline A1C of 7.5 % and BMI of 34 kg/m². Participants receiving the 4.1 mg dose experienced a 0.34 % reduction in A1C, with more than half achieving the <7 % guideline, while higher doses produced dose‑responsive weight loss up to 7 % and insulin reductions up to 15 %. Continuous glucose monitoring confirmed tighter glycemic excursions, and safety data showed no new adverse signals. These outcomes echo the efficacy seen in type 2 trials, suggesting that dual GLP‑1/GIP agonism can deliver insulin‑independent benefits even when basal insulin is required.

If larger phase 3 programs replicate these findings, acmopatide could become the first FDA‑approved adjunct for type 1 diabetes, opening a multi‑billion‑dollar market for non‑insulin therapies. Payers may favor a drug that lowers insulin consumption and mitigates obesity‑related complications, potentially reducing long‑term healthcare costs. Moreover, the trial’s success may spur further research into combination hormone therapies, expanding the therapeutic toolbox for endocrinologists and improving quality of life for millions of Americans living with type 1 diabetes.